FDA Enforcement Class II Ongoing

BD BBL Sensi Disc Ceftriaxone- 30 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231634 and 231635¿

Recall: Z-1024-2024 · Reported February 14, 2024

Enforcement

Recall Number
Z-1024-2024
Event ID
93789
Classification
Class II
Status
Ongoing
Product Type
Devices
Firm
Becton Dickinson & Co.
Voluntary / Mandated
Voluntary: Firm initiated
Initial Notification
Letter
Report Date
February 14, 2024
Initiation Date
January 8, 2024
Classification Date
February 8, 2024
Address
7 Loveton Cir, Sparks, MD, 21152-9212, United States

Description

BD BBL Sensi Disc Ceftriaxone- 30 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231634 and 231635¿

Reason

There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.

Code Info

Catalog No. 231634 UDI-DI 00382902316343 Lots 1033870 1244758 2026381 2056573 2277488; Catalog No. 231635¿ UDI-DI 30382902316351 Lots 3062288 3158099 3254299 0344489 1033870 1088039 1116107 1148606 1180379 1211608 1244758 1335697 2026381 2028922 2056573 2180451 2277488 2277490

Distribution

Domestic distribution nationwide. International distribution worldwide.

Quantity

2,363,168 total units